Chief Medical Officer
Nicolas Leupin joined argenx as CMO in February 2016. Dr Leupin brings clinical and industry expertise in medical oncology as well as experience in drug development to the Company. In his previous role, Dr Leupin was the clinical lead of several hematology/oncology clinical trials, including both academic cooperative group and industry-sponsored trials, several of them through to registration. Dr Leupin, who is board certified medical oncologist went to medical school in Bern, Switzerland. He first started his career in the department of pathology of the University of Bern where he discovered his passions for tumor biology, research and teaching. He continued with a fellowship in cancer molecular biology. After 2 years at the bench he returned to clinical medicine. He spent several years in academia, at the bedside of patients and specialized in medical oncology with a special interest in hematological oncology. Dr. Leupin became member of the Swiss Cancer Research Group (SAKK) and board member of the lymphoma team. After those years of clinical activity he was offered to join Celgene to help building the clinical development department in Europe. He was assigned to the lymphoma team, some years later to the myeloma team, Celgene’s prime indication, where he was instrumental in leading the European teams and in bridging with the US teams. Nicolas was Global Clinical Lead for several compounds up to phase III, where among other activities he was responsible for the summary of efficacy of registration dossiers that lead to successful European and American registrations. Nicolas Leupin holds an MBA with a focus on negotiation and conflict management, participated in various postgraduate courses, including the IMD in Lausanne. He keeps an academic activity and is still lecturer at the University of Bern.
drug development and reserach